Palonosetron

Jump to: navigation, search
Palonosetron
Palonosetron Wiki Str.png
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa610002
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
administration
Intravenous, oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability97% (oral)
Protein binding62%
MetabolismHepatic, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)
Elimination half-lifeApproximately 40 hours
ExcretionRenal, 80% (of which 49% unchanged); fecal (5 to 8%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H24N2O
Molar mass296.407 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Palonosetron

Articles

Most recent articles on Palonosetron

Most cited articles on Palonosetron

Review articles on Palonosetron

Articles on Palonosetron in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Palonosetron

Images of Palonosetron

Photos of Palonosetron

Podcasts & MP3s on Palonosetron

Videos on Palonosetron

Evidence Based Medicine

Cochrane Collaboration on Palonosetron

Bandolier on Palonosetron

TRIP on Palonosetron

Clinical Trials

Ongoing Trials on Palonosetron at Clinical Trials.gov

Trial results on Palonosetron

Clinical Trials on Palonosetron at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Palonosetron

NICE Guidance on Palonosetron

NHS PRODIGY Guidance

FDA on Palonosetron

CDC on Palonosetron

Books

Books on Palonosetron

News

Palonosetron in the news

Be alerted to news on Palonosetron

News trends on Palonosetron

Commentary

Blogs on Palonosetron

Definitions

Definitions of Palonosetron

Patient Resources / Community

Patient resources on Palonosetron

Discussion groups on Palonosetron

Patient Handouts on Palonosetron

Directions to Hospitals Treating Palonosetron

Risk calculators and risk factors for Palonosetron

Healthcare Provider Resources

Symptoms of Palonosetron

Causes & Risk Factors for Palonosetron

Diagnostic studies for Palonosetron

Treatment of Palonosetron

Continuing Medical Education (CME)

CME Programs on Palonosetron

International

Palonosetron en Espanol

Palonosetron en Francais

Business

Palonosetron in the Marketplace

Patents on Palonosetron

Experimental / Informatics

List of terms related to Palonosetron

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV—nausea and vomiting and there are tentative data to suggest that it may be better than granisetron.[1]

Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy,[2] or as a single oral capsule one hour before chemotherapy.[3] The oral formulation was approved on August 22, 2008 for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV.[3]

See also

References

  1. Billio, A; Morello, E; Clarke, MJ (Jan 20, 2010). "Serotonin receptor antagonists for highly emetogenic chemotherapy in adults". The Cochrane database of systematic reviews (1): CD006272. doi:10.1002/14651858.CD006272.pub2. PMID 20091591.
  2. De Leon A (2006). "Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting". Proceedings (Baylor University. Medical Center). 19 (4): 413–6. PMC 1618755. PMID 17106506.
  3. 3.0 3.1 Waknine, Yael (September 4, 2008). "FDA Approvals: Nplate, Aloxi, Vidaza". Medscape. Retrieved 2008-09-04. Freely available with registration.


Template:Gastrointestinal-drug-stub


Linked-in.jpg